Plus Therapeutics, Inc. (NASDAQ:PSTV) Short Interest Up 134.4% in February

Plus Therapeutics, Inc. (NASDAQ:PSTV) saw a significant growth in short interest in February. As of February 28th, there was short interest totalling 140,400 shares, a growth of 134.4% from the February 13th total of 59,900 shares. Based on an average daily volume of 7,730,000 shares, the short-interest ratio is currently 0.0 days. Currently, 2.4% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of brokerages have issued reports on PSTV. Ascendiant Capital Markets reduced their price objective on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research report on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price target on shares of Plus Therapeutics in a research report on Tuesday, November 26th.

Plus Therapeutics Trading Down 9.5 %

Shares of NASDAQ:PSTV traded down $0.07 during mid-day trading on Friday, reaching $0.68. The company had a trading volume of 2,448,675 shares, compared to its average volume of 10,429,443. The company’s 50-day moving average price is $1.13 and its 200-day moving average price is $1.26. Plus Therapeutics has a one year low of $0.24 and a one year high of $2.67. The firm has a market cap of $4.00 million, a price-to-earnings ratio of -0.27 and a beta of 0.73.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.